Psoriatic Arthritis
Latest News
Study Supports Efficacy of Home-Based Phototherapy for Psoriasis
"Efforts are needed to make home and office phototherapy more available to patients," the lead author said.
News from the FDA/CDC
Bimekizumab Gains FDA Approval for Psoriatic Arthritis, Axial Spondyloarthritis
The drug is the first and only dual IL-17A and IL-17F inhibitor approved to treat four chronic immune-mediated inflammatory diseases.
Latest News
Topical Tapinarof and Roflumilast for Psoriasis: Where Do they Fit In?
“They’re very fast-acting, effective,” and result in a large improvement over steroids, Dr. Jashin Wu said.
Feature
Ustekinumab’s ‘Egregious’ Medicare Part B and D Pricing Differences Led to Federal Intervention
OIG reports showed a spike in ustekinumab costs for patients in Medicare Part D. Experts said Inflation Reduction Act changes in Medicare drug...
News
New Associations Identified Between IBD and Extraintestinal Manifestations
Overall, 14% of patients had at least one extraintestinal manifestation.
Latest News
TYK2 Inhibitor Effective for Psoriasis in Phase 2 Study
At week 12, PASI 75 was achieved by 18%, 44%, 68%, and 67% of patients receiving zasocitinib at doses of 2 mg, 5 mg, 15 mg, and 30 mg,...
From the Journals
Patients With Immune-Mediated Inflammatory Diseases, Type 2 Diabetes Reap GLP-1 Receptor Agonist Benefits, Too
GLP-1 RAs were associated with a decreased risk for all-cause mortality and major adverse cardiovascular events in patients with immune-mediated...
Feature
Do You Have Patients With JAKne — JAK Inhibitor–Associated Acne? Here’s What to Know
Janus kinase (JAK) inhibitor-associated acne may be overlooked outside of dermatology, experts said.
From the Journals
US Experience With Infliximab Biosimilars Suggests Need for More Development Incentives
Use of infliximab biosimilars in the United States rose slowly until three were on the market; it continued to remain lower for Medicare than for...
Latest News
Advantages of a Pediatric Rheumatology/Dermatology Clinic Evaluated
The top four primary diagnoses at the clinic were linear morphea (33%), lupus (23%), ...
Latest News
Study Finds Differences in Side Effect Profiles With Two Oral Psoriasis Therapies
The results were based on data from the FDA’s Adverse Event Reporting System.